# Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

> **NCT04804813** · — · COMPLETED · sponsor: **Takeda** · enrollment: 388 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT04804813
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-29
- **Primary completion:** 2024-07-25
- **Final completion:** 2024-07-25
- **Target enrollment:** 388 (ACTUAL)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04804813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04804813, "Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04804813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*